MRD Focus: why measurable residual disease testing is the future
Bruno Paiva et al.
Future of aggressive lymphoma treatment: a shift towards chemo-free regimens
Results of the COG AALL0434 trial for T-cell malignancies
Venetoclax: an unmet need in R/R mantle cell lymphoma after BTK inhibitors
Positive results for acalabrutinib in Waldenström's macroglobulinemia